肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效  

Clinical Efficacy of Pulmonary Surfactant for the li-eatment of Neonatal Respiratory Distress Syndrome

作　　者：贾小芳[1] 黄燕霞[1] 

机构地区：[1]西安市儿童医院,陕西西安710003

出　　处：《医学临床研究》2012年第7期1283-1284,共2页Journal of Clinical Research

摘　　要：【目的】观察肺表面活性物质（PS）治疗新生儿呼吸窘迫综合征（NRDS）的疗效。【方法】对本院115例NRDS患儿在给予机械通气治疗的基础上分为两组，治疗组（71例）加用PS治疗，对照组（44例）未加用PS。观察比较治疗前后两组患儿的临床疗效。【结果】治疗组在应用PS后患儿呼吸困难、呻吟、三凹征、发绀症状减轻或消失。用药1h后以及24h后，复查血气分析示动脉氧分压（PaO2）升高、二氧化碳分压（PaCO2）下降、pH值由略偏低变为正常，与治疗前及对照组相比差异均有显著性（P〈0．05）。用药6～8h后，复查胸片示治疗组肺部病变显著改善比例为50．7％，48h后复查胸片，治疗组肺部基本正常者为90．1％，均明显高于与对照组，两组相比较差异均有显著性（P〈0．05）。【结论】PS治疗NRDS疗效较显著，能有效改善患儿肺通气、换气功能。[Objective] To observe the efficacy of pulmonary surfactant（PS） for the treatment of neonatal respiratory distress syndrome（NRDS）. [Methods] Totally 115 pediatric patients with NRDS receiving mechan- ical ventilation treatment were divided into two groups. The treatment group（ n = 71） additionally received PS treatment. Control group（ n =44） didn＇t received PS treatment. The clinica,1 efficacy of two groups were ob- served and compared between before and after treatment. [Results] The symptoms such as dyspnea, groa- ning, three-concave sign and cyanosis in pediatric patients of treatment group after PS treatment were allevia- ted or disappeared. Te reexamination of blood gas at 1 and 14 hours after administration showed that PaO2 in- creased and PaCO2 decreased, and pH value became normal from slightly low, and there were significant differences compared with before treatment and control group（ P 〈0.05）. At 6 to 8 hours after treatment, the reexamination of chest X-ray showed that patients with the improvement of lung lesion in treatment group occupied 50.7%. At 48 hours after treatment, the reexamination of chest X-ray showed that the patients with the normal lung occupied 90.1% which was obviously higher than that those in control group, and there was significant difference between two groups（ P 〈0.05）. [Conclusion] PS（Curosurf） for the treatment of NRDS has significant efficacy. It can effectively improve lung ventilation and exchange function.

关 键 词：呼吸窘迫综合征/药物疗法 肺表面活性剂/治疗应用 婴儿 新生 疾病 

分 类 号：R725.63[医药卫生—儿科]